Avience Biomedicals IPO
Avience Biomedicals IPO Listing Day Performance
Avience Biomedicals listed on NSE SME on 25 June 2026 at ₹395.20, a 90% premium over the issue price of ₹208. A retail investor allotted the minimum application of 1,200 shares (2 lots) gained ₹2,24,640 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹107 (+51.4%) |
| GMP-implied listing | ₹315 |
| Actual listing | ₹395.20 |
| Difference | +₹80.2 (+25.5%) |
Demand going into listing
| Subscribed overall | 385.4× |
| QIB | 196.77× |
| NII | 597.63× |
| Retail | 401.36× |
Market Sentiment
The overall score is a weighted average of the parts below, so one weak part can sit inside a strong overall reading.
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 5 |
|---|---|---|---|
| QIB | 0.00x | 0.03x | 196.77x |
| NII | 13.43x | 66.63x | 597.63x |
| bNII > ₹10L | 13.66x | 66.67x | 670.77x |
| sNII 2-10L | 12.96x | 66.56x | 451.35x |
| Retail | 15.23x | 58.02x | 401.36x |
| Total | 9.68x | 39.96x | 385.40x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2024 | 2025 | Jan 2026 |
|---|---|---|---|
| Revenue | 24.37 | 45.97 | 41.94 |
| Expense | 21.43 | 36.17 | 34.06 |
| Profit (PAT) | 2.14 | 7.23 | 5.74 |
| Total Assets | 34.65 | 56.52 | 66.07 |
Promoters & Holding Pattern
Promoters: Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 40,31,256 | 87.89% |
| Promoter Holding Post Issue | 54,85,056 | 64.59% |
Strengths & Risks
- Heavily oversubscribed — 385.4x overall (so far).
- Strong institutional (QIB) demand — 196.8x.
- Revenue grew 89% in the latest reported year.
- Solid profit margin — 15.7%.
- Strong return on equity — 50%.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
About Avience Biomedicals
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products. Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices. The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas as well. Along with manufacturing, the firm also serves as a distributor and trader of medical equipment. Moreover, its manufacturing facility is located in Noida, Uttar Pradesh.
Company Contact Information
Avience Biomedicals Ltd., C-11, Block-C, Community Centre,, Janakpuri A-3,, Delhi, New Delhi, 110058
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 15.96 |
| Funding the working capital requirements of the Company | 8.25 |
| General Corporate Purpose | - |
Resources & Documents
Anchor Investors
Avience Biomedicals IPO - Quick Take
Avience Biomedicals has set a price band of Rs 196–Rs 208 per share for an issue size of Rs 30 crore. The stock listed with a 90.00% gain versus its issue price on June 25, 2026.
The issue is promoted by Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary with Fintellectual Corporate Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 2… (Rs 16 crore) and funding the working capital requirements of the Company (Rs 8 crore).
On fundamentals, the company is posting revenue growth of 88.6%, a profit margin of 15.7%, return on equity of 49.9% in its most recent reported period.
On our data-signal score, the combined signals for this issue currently read very strong — GMP, subscription demand and fundamentals are all reading positively. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Frequently Asked Questions
Avience Biomedicals IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed. Its last GMP before listing was 51.4%. Of the 32 SME IPOs we have tracked with a final GMP of 25% or more, 32 listed above, 0 flat and 0 below the issue price; Avience Biomedicals listed 90% above its issue price.
See the full Avience Biomedicals GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Avience Biomedicals
No comments yet. Be the first to share your opinion!